102767-28-2
102767-28-2
Chemical Structure
Levetiracetam
Synonym(s): UCB L059
- CAS No.: 102767-28-2
- Formula:C8H14N2O2
- Molecular Weight:170.21
IUPAC Name: (S)-2-(2-oxopyrrolidin-1-yl)butanamide
InChIKey: HPHUVLMMVZITSG-LURJTMIESA-N
SMILES: NC([C@@H](N(CCC1)C1=O)CC)=O
Biological Activity: Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Levetiracetam | 99.98% | Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levetiracetam (Standard) | 99.96% | Levetiracetam (Standard) is the analytical standard of Levetiracetam. This product is intended for research and analytical applications. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levetiracetam-d6 | Levetiracetam-d6 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levetiracetam-d3 | Levetiracetam-d3 is the deuterium labeled Levetiracetam. Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Levetiracetam-d6 (ring-d6) | 98.70% | Levetiracetam-d6 (ring-d6) can be used as internal standard for the determination of Levetiracetam (HY-B0106) content in whole blood. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bianca Maria Scicchitano, et al. Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 2018 Sep 10;18:136. [Content Brief]
- [2]. Delia M Talos, et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res. 2013 Jan;73(1):24-30. [Content Brief]
